The Jeito fund completes its first major sale

2022-11-29T19:33:50.745Z

AstraZeneca is buying Dutch biotech Neogene for $320 million. It's a nice move for Jeito. Nearly three years after its creation, this European venture capital fund specializing in health has completed its first sale to a Big Pharma. The AstraZeneca laboratory acquires the Dutch biotech Neogene Therapeutics, specialized in oncology, for a total amount of up to 320 million dollars. Jeito, who was the first shareholder, accompanied Neogene for two years. He the

It's a nice move for Jeito.

Nearly three years after its creation, this European venture capital fund specializing in health has completed its first sale to a Big Pharma.

The AstraZeneca laboratory acquires the Dutch biotech Neogene Therapeutics, specialized in oncology, for a total amount of up to 320 million dollars.

Jeito, who was the first shareholder, accompanied Neogene for two years.

He then co-led a first round of funding of 110 million dollars.

“

This operation validates Jeito's strategy, which consists in accelerating the access of patients in therapeutic impasse to new treatments,

summarizes Rafaèle Tordjman, founder of Jeito, which has 534 million euros under management.

We do this by staying as close as possible to the needs of major pharmaceutical companies, while offering as many options as possible to the companies we support.”

To discover